ADCC Reporter Bioassay: A Novel, Bioluminescent Cell-Based Assay for Quantifying Fc...
ADCC Reporter Bioassay: A Novel, Bioluminescent Cell-Based Assay for Quantifying Fc Effector Function of Antibodies
Get Involved With Our Webinars
Richard is a Strategic Collaborations Manager at Promega and part of a team focused on building strategic relationships with pharmaceutical and biotech companies via early access to technologies, custom assay services, and collaborative support. Prior to his position at Promega, Dr. Somberg worked at Life Technologies, where he led product development and service efforts in biochemical and cell-based assays for key target classes in drug discovery. He completed post-doctoral studies at the University of Pennsylvania, received his Ph.D. in immunology from Purdue University, and a Bachelor of Science in genetics and development from the University of Illinois.
Richard Somberg, Ph.D.
Strategic Collaborations Manager
- See speaker bio
- Original Webinar Date: Tuesday, October 23, 2012
The ADCC Reporter Bioassay is a bioluminescent cell-based assay that can be used across biologics drug development programs to quantify the potency of Fc effector function of therapeutic monoclonal antibodies. The novel bioassay demonstrates all the performance hallmarks of a QC release bioassay and is a suitable replacement for cumbersome and highly variable cytotoxic ADCC assays.
Antibody dependent cell-mediated cytotoxicity (ADCC) assays are typically performed using PBMCs or NK cells and suffer from high variability and poor reproducibility. To circumvent these issues, Promega has developed a reporter-based ADCC bioassay using an effector cell line that stably expresses an NFAT luciferase response element and human FcgIIIa high affinity (V158) receptor. When the effector cells are exposed to antibodies bound to target cells, activation of the FcgIIIa receptor signaling pathway occurs resulting in increased luciferase activity, which correlates to cytotoxic ADCC assays. By eliminating PBMCs or NK cells, the assay reproducibility is greatly increased and the variability is significantly reduced, while retaining the ability to discriminate antibodies with varying degrees of Fc effector function. The novel ADCC Reporter Bioassay contains effector cells in frozen, thaw-and-use format, which greatly reduces hands-on preparation typically required for an ADCC assay. Following DOE studies, the ADCC Reporter Bioassay was tested with FDA-approved antibodies (i.e., rituximab and trastuzumab) in qualification studies and the assay showed excellent linearity, accuracy, and precision. Studies using treated samples demonstrated the assay to be stability-indicating. Furthermore, the assay shows good linear correlation between levels of glycosylation and afucosylation with ADCC activity. Overall, the ADCC Reporter Bioassay is able to quantify Fc effector functionality and is a suitable replacement for classic cytotoxic ADCC assays, when low variability and high reproducibility are required.